Regenxbio Inc (RGNX) Insider Sells $921,600.00 in Stock

Regenxbio Inc (NASDAQ:RGNX) insider Kenneth T. Mills sold 15,000 shares of Regenxbio stock in a transaction dated Wednesday, November 21st. The stock was sold at an average price of $61.44, for a total value of $921,600.00. Following the sale, the insider now directly owns 284,700 shares in the company, valued at $17,491,968. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

NASDAQ RGNX traded up $1.89 during trading on Monday, reaching $64.99. 268,300 shares of the company traded hands, compared to its average volume of 532,854. The company has a market capitalization of $2.26 billion, a price-to-earnings ratio of -26.53, a PEG ratio of 9.61 and a beta of -0.49. Regenxbio Inc has a 1-year low of $23.25 and a 1-year high of $85.10.

Regenxbio (NASDAQ:RGNX) last released its quarterly earnings data on Wednesday, November 7th. The biotechnology company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.30. The company had revenue of $5.31 million for the quarter. Regenxbio had a return on equity of 22.52% and a net margin of 44.30%. Equities analysts expect that Regenxbio Inc will post 2.16 EPS for the current year.

A number of research firms recently weighed in on RGNX. Zacks Investment Research raised Regenxbio from a “hold” rating to a “buy” rating and set a $78.00 target price on the stock in a research report on Wednesday, November 7th. BidaskClub downgraded Regenxbio from a “buy” rating to a “hold” rating in a research report on Tuesday, November 13th. Raymond James set a $96.00 target price on Regenxbio and gave the stock a “buy” rating in a research report on Thursday, November 8th. ValuEngine raised Regenxbio from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 10th. Finally, Bank of America lifted their target price on Regenxbio from $76.00 to $84.00 and gave the stock a “neutral” rating in a research report on Thursday, November 8th. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $82.93.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in Regenxbio by 51.0% during the third quarter. Vanguard Group Inc. now owns 2,805,969 shares of the biotechnology company’s stock valued at $211,851,000 after purchasing an additional 947,671 shares in the last quarter. Legal & General Group Plc boosted its holdings in Regenxbio by 30.9% during the third quarter. Legal & General Group Plc now owns 69,908 shares of the biotechnology company’s stock valued at $5,281,000 after purchasing an additional 16,522 shares in the last quarter. Kepos Capital LP acquired a new stake in Regenxbio during the third quarter valued at approximately $5,155,000. Teachers Advisors LLC boosted its holdings in Regenxbio by 6.5% during the third quarter. Teachers Advisors LLC now owns 221,979 shares of the biotechnology company’s stock valued at $16,759,000 after purchasing an additional 13,537 shares in the last quarter. Finally, AQR Capital Management LLC boosted its holdings in Regenxbio by 20.4% during the third quarter. AQR Capital Management LLC now owns 211,830 shares of the biotechnology company’s stock valued at $15,993,000 after purchasing an additional 35,915 shares in the last quarter. 75.92% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by WKRB News and is the sole property of of WKRB News. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.wkrb13.com/2018/11/27/regenxbio-inc-rgnx-insider-sells-921600-00-in-stock.html.

Regenxbio Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

Recommended Story: Can individual investors take part in an IPO?

Insider Buying and Selling by Quarter for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply